BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND KDM6A, O15550, UTX, 7403, ENSG00000147050, DKFZp686A03225, RP13-886N14_3, MGC141941, bA386N14_2 AND Treatment
17037 results:

  • 1. Oocyte collection and outcome following oncologic treatment: a retrospective multicentre study.
    Fernández-González MJ; Borgmann-Staudt A; Llagostera CG; Ceballos-Garcia E; Gebauer J; Jantke A; Barnbrock A; Kentenich H; Klco-Brosius S; Lotz L; Balcerek M
    Support Care Cancer; 2024 May; 32(6):390. PubMed ID: 38806697
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Impact of Mitochondria in ovarian cancer Cell Metabolism, Proliferation, and Metastasis.
    Schatten H
    Adv Exp Med Biol; 2024; 1452():119-125. PubMed ID: 38805128
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Tubulin Complexity in cancer and Metastasis.
    Danziger M; Xu F; Noble H; Yang P; Roque DM
    Adv Exp Med Biol; 2024; 1452():21-35. PubMed ID: 38805123
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
    Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
    Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
    [No Abstract]    [Full Text] [Related]  

  • 6. Transcriptome profiling and characterization of peritoneal metastasis ovarian cancer xenografts in humanized mice.
    Kang SW; Lee JY; Kang OJ; Kim YM; Choi EK; Lee SW
    Sci Rep; 2024 May; 14(1):11894. PubMed ID: 38789484
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
    Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
    Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer.
    Erturk A; Korkmaz E; Arslantas Z; Bekdemir S; Erturk NK
    Rev Assoc Med Bras (1992); 2024; 70(5):e20231115. PubMed ID: 38775501
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Racial and Ethnic Inequities in cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
    Islam JY; Hathaway CA; Hume E; Turner K; Hallanger-Johnson J; Tworoger SS; Camacho-Rivera M
    JAMA Netw Open; 2024 May; 7(5):e2412050. PubMed ID: 38767916
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Construction and Validation of a Nomogram to Predict the Postoperative Venous Thromboembolism Risk in Patients with HGSOC.
    Huang Z; Li L; Gong Z; Tang L
    Clin Appl Thromb Hemost; 2024; 30():10760296241255958. PubMed ID: 38767088
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
    Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
    Liu Y; Shi W; Mubarik S; Wang F
    BMC Public Health; 2024 May; 24(1):1349. PubMed ID: 38764017
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
    Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
    JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.
    Qin Y; Sheng Y; Ren M; Hou Z; Xiao L; Chen R
    Sci Rep; 2024 May; 14(1):11133. PubMed ID: 38750159
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
    Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
    J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The Role of Palliative Surgery in the Management of Acute Intestinal Obstruction Secondary to Peritoneal Carcinomatosis.
    Bhat BK; Yadav A; Nundy S
    Chirurgia (Bucur); 2024 Apr; 119(2):218-226. PubMed ID: 38743835
    [No Abstract]    [Full Text] [Related]  

  • 19. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
    Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
    BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 852.